Omics-Driven Biomarker Discovery for Psoriasis
The advent of omics technologies has revolutionized the landscape of biomarker discovery, enabling a deeper understanding of disease mechanisms at the molecular level. At Ace Therapeutics, we specialize in leveraging omics technologies to support the identification and validation of biomarkers in the pathogenesis of psoriasis.
Introduction to Omics-Driven Biomarker Discovery
The complexity of psoriasis pathogenesis, involving intricate interplay of genetic, environmental, and immunological factors, necessitates a deeper understanding of the underlying molecular mechanisms. Emerging evidence suggests that a systems-level approach, integrating various omics data, can provide valuable insights into the complex pathogenesis of psoriasis. By leveraging advanced technologies in genomics, transcriptomics, proteomics, and metabolomics, researchers have identified numerous candidate biomarkers with potential diagnostic, prognostic, and therapeutic implications.
Fig. 1 The workflow of biomarker discovery. (Aydin B, et al., 2020)
Comprehensive Omics-Driven Biomarker Discovery for Psoriasis
At Ace Therapeutics, we offer a comprehensive suite of omics-driven biomarker discovery services tailored to the needs of our clients in the psoriasis research and drug development landscape. Our seasoned scientific team is equipped to provide our clients with unparalleled insights into the disease pathogenesis.
| Service Options | Methodologies | Insights |
| Transcriptomic Profiling | RNA-sequencing Microarray analysis |
Elevated levels of inflammatory cytokines (e.g., IL-17, IL-23, TNF-α) Increased expression of chemokines (e.g., CCL20, CXCL1, CXCL5) Altered expression of antimicrobial peptides (e.g., S100A7, S100A8, S100A12) |
| Epigenomic Profiling | DNA methylation analysis Histone modification profiling |
Differentially methylated regions in key genes (SHP-1, ID4, p15, PTPN22) Dysregulated miRNAs (miR-203, miR-146b, miR-143, miR-223) Aberrantly expressed lncRNAs (PRINS, CYP4Z2P, HINT1) |
| Proteomic Profiling | Mass spectrometry Antibody-based assays |
Elevated levels of S100 proteins (S100A7, S100A8, S100A12) Altered expression of proteases (KLK7, SCCA2) and their inhibitors Dysregulation of cell adhesion and angiogenesis-related proteins |
| Metabolomic Profiling | Liquid chromatography-mass spectrometry (LC-MS) Nuclear magnetic resonance (NMR) spectroscopy |
Dysregulation of lipid metabolism (arachidonic acid, 12-HETE) Imbalances in amino acid metabolism (asparagine, glutamine, ornithine) Interference with glycolysis and other central metabolic pathways |
| Glycomic Profiling | Lectin arrays High-performance liquid chromatography (HPLC) |
Altered expression of glycosyltransferases and glycosidases Alterations in the abundance of specific glycan structures Dysregulation of cell surface glycoproteins involved in inflammation |
At Ace Therapeutics, we are committed to supporting psoriasis research and drug development through our omics-driven biomarker discovery services. By harnessing the power of multi-omics technologies, we are unraveling the intricate molecular landscapes of this complex skin disease, paving the way for antipsoriatic drug development. Contact us today to learn more about our services and how we can tailor our offerings to meet your unique research needs.
Reference
- Aydin B, et al. Omics-Driven Biomarkers of Psoriasis: Recent Insights, Current Challenges, and Future Prospects. Clin Cosmet Investig Dermatol. 2020;13:611-625.